Literature DB >> 8857729

Function changes in spinal muscular atrophy II and III. The DCN/SMA Group.

B S Russman1, C R Buncher, M White, F J Samaha, S T Iannaccone.   

Abstract

The course of spinal muscular atrophy (SMA) is not well established except for those patients whose age of onset is before 6 months and who achieve only "sit with support" as their maximum function (Werdnig-Hoffmann disease or SMA I). This study shows that there is another group of SMA patients whose age of onset and maximum function achieved can be used as prognostic guides. Fifty percent of SMA patients who could walk without assistance and whose onset was prior to age 2 years lost the ability to walk independently by age 12. Fifty percent of SMA patients who walked and whose onset was between 2 and 6 years of age lost walking ability by age 44 years. Fifty percent of SMA patients who could walk with assistance as their best function ever achieved lost this ability by age 7 years, unrelated to age of onset; none could walk with assistance after age 14 years. Seventy-five percent of SMA patients who developed the ability to sit independently as their best function were still sitting after age 7 years independent of age of onset; 50% of this group could sit independently after age 14 years. Eighty-five percent of SMA patients who could walk could not negotiate stairs without holding onto a rail. They could raise their hands above the head; however, as they lost walking ability, they lost this function as well. Only one SMA patient whose maximum function was sitting independently could get to the sitting position on his own. Only two of these patients could hold their hands above their heads. All patients with SMA lose function over time. This function loss occurs slowly and is related primarily to maximum function achieved; knowledge of age of onset provides helpful information, especially for predicting the loss of independent walking.

Entities:  

Mesh:

Year:  1996        PMID: 8857729     DOI: 10.1212/wnl.47.4.973

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy.

Authors:  Kristin J Krosschell; Jo Anne Maczulski; Thomas O Crawford; Charles Scott; Kathryn J Swoboda
Journal:  Neuromuscul Disord       Date:  2006-06-05       Impact factor: 4.296

2.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

3.  Compound muscle action potential and motor function in children with spinal muscular atrophy.

Authors:  Aga Lewelt; Kristin J Krosschell; Charles Scott; Ai Sakonju; John T Kissel; Thomas O Crawford; Gyula Acsadi; Guy D'anjou; Bakri Elsheikh; Sandra P Reyna; Mary K Schroth; Jo Anne Maczulski; Gregory J Stoddard; Elie Elovic; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2010-11       Impact factor: 3.217

Review 4.  New therapeutic approaches to spinal muscular atrophy.

Authors:  Aga Lewelt; Tara M Newcomb; Kathryn J Swoboda
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

5.  Therapeutic developments in spinal muscular atrophy.

Authors:  Douglas M Sproule; Petra Kaufmann
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

6.  Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy.

Authors:  Kristin J Krosschell; Charles B Scott; Jo Anne Maczulski; Aga J Lewelt; Sandra P Reyna; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2011-06-22       Impact factor: 3.217

Review 7.  Spinal muscular atrophy.

Authors:  Susan T Iannaccone; Stephen A Smith; Louise R Simard
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

8.  Temporal requirement for SMN in motoneuron development.

Authors:  Le T Hao; Phan Q Duy; James D Jontes; Marc Wolman; Michael Granato; Christine E Beattie
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

Review 9.  Spinal muscular atrophy and the antiapoptotic role of survival of motor neuron (SMN) protein.

Authors:  Ryan S Anderton; Bruno P Meloni; Frank L Mastaglia; Sherif Boulos
Journal:  Mol Neurobiol       Date:  2013-01-13       Impact factor: 5.590

10.  A natural history study of late onset spinal muscular atrophy types 3b and 4.

Authors:  S Piepers; L H van den Berg; F Brugman; H Scheffer; M Ruiterkamp-Versteeg; B G van Engelen; C G Faber; M de Visser; W-L van der Pol; J H J Wokke
Journal:  J Neurol       Date:  2008-06-30       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.